132
Participants
Start Date
January 9, 2023
Primary Completion Date
February 29, 2028
Study Completion Date
February 29, 2028
ATRN-119
ATRN-119 is a capsule formulation that will be supplied as 50 mg and 100 mg capsules packed in sealed plastic bottles (n=30) and dispensed by the site pharmacist in combinations to provide the appropriate dose.
RECRUITING
Jordan Center for Gynecologic Oncology at Penn Perelman Center for Advanced Medicine, Philadelphia
RECRUITING
NEXT Oncology- Virginia, Fairfax
RECRUITING
University Hospitals, Cleveland Medical Center, Cleveland
RECRUITING
NEXT- Oncology Dallas, Irving
RECRUITING
Mary Crowley Cancer Research, Dallas
RECRUITING
NEXT Oncology- San Antonio, San Antonio
RECRUITING
Yale Cancer Center, New Haven
Lead Sponsor
Aprea Therapeutics
INDUSTRY